Estelamari Rodriguez

1 month ago | onclive.com | Estelamari Rodriguez |Tarek Mekhail |Balazs Halmos |Susan Scott |Julie R. Brahmer |Corey J Langer | +1 more

CommentaryVideoApril 30, 2025Author(s):,Fact checked by:,Lung cancer experts discuss successes and hesitations regarding the evolving use of antibody-drug conjugates in non–small cell lung cancer.

Jan 6, 2025 | onclive.com | Estelamari Rodriguez

Estelamari Rodriguez, MD, MPH, discusses how to overcome disparities in cancer care. Estelamari Rodriguez, MD, MPH, discusses how to overcome disparities in cancer care.

Feb 2, 2024 | onclive.com | Estelamari Rodriguez

February 2, 2024Estelamari Rodriguez, MD, MPH, discusses adverse effects associated with HER2-directed antibody-drug conjugates in non–small cell lung cancer.

May 18, 2023 | futuremedicine.com | Edgardo S. Santos |Estelamari Rodriguez |Boca Raton

Lung Cancer ManagementAhead of PrintPlain Language Summary of PublicationOpen AccessAbstractWhat is this article about? This plain language summary reports the key points of a recent review article that discussed current treatment options for a type of cancer called squamous cell carcinoma (SCC) of the lung. What is SCC of the lung? SCC of the lung is a type of non-small-cell lung cancer (NSCLC for short) that is usually linked with smoking.